Skip to main content

9 Result(s)

within T. Sunderland Remove this filter

and

  1. No Access

    Article

    β-Amyloid augments platelet aggregation: reduced activity of familial angiopathy-associated mutants

    The β-amyloid (Aβ) peptide is present both in serum and in platelets, however it is unclear whether Aβ plays a role in platelet function. We have now investigated the effects of soluble Aβ on platelet function...

    B Wolozin, S Maheshwari, C Jones, R Dukoff, W Wallace, M Racchi… in Molecular Psychiatry (1998)

  2. No Access

    Chapter and Conference Paper

    Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline)

    Marked, dose-dependent elevations in the urinary excretion of phenylethylamine, para-tyramine, and meta-tyramine were observed in depressed patients treated for three or more weeks with 10, 30, or 60 mg/ day o...

    Dr. D. L. Murphy, F. Karoum, D. Pickar… in MAO — The Mother of all Amine Oxidases (1998)

  3. No Access

    Article

    Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study

    The effects of low-dose chronic scopolamine on measures of cerebral perfusion and muscarinic receptors were tested in eight Alzheimer's disease (AD) subjects and eight elderly controls. Single photon emission ...

    T. Sunderland, G. Esposito, S. E. Molchan, R. Coppola, D. W. Jones… in Psychopharmacology (1995)

  4. No Access

    Article

    Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans

    Cholinergic neurotransmission is thought to be modulated by serotonin as documented in animal and human studies. We examined the effects of the muscarinic antagonist scopolamine (0.4 mg IV) given alone or toge...

    J. T. Little, A. Broocks, A. Martin, J. L. Hill, L. E. Tune, C. Mack… in Psychopharmacology (1995)

  5. No Access

    Chapter

    The need for early markers in Alzheimer’s disease

    Currently, there are no definitive early markers for Alzheimer’s disease (AD) or senile dementia of the Alzheimer type (SDAT). Nonetheless, there are some interesting marker candidates under evaluation. Severa...

    D. L. Murphy, T. Sunderland in Early Markers in Parkinson’s and Alzheimer’s Diseases (1990)

  6. No Access

    Article

    Intravenous nicotine in Alzheimer's disease: a pilot study

    In the first study to examine direct nicotinic augmentation of central cholinergic functioning in Alzheimer's disease, six patients were studied in an intensive pilot study with three doses (0.125, 0.25, and 0...

    P. A. Newhouse, T. Sunderland, P. N. Tariot, C. L. Blumhardt… in Psychopharmacology (1988)

  7. No Access

    Article

    Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease

    Deprenyl, a monoamine oxidase (MAO) inhibitor with selective effects on MAO type-B at low doses, was administered to 13 patients with dementia of the Alzheimer type (DAT), a disorder reported to be associated ...

    T. Sunderland, P. N. Tariot, R. M. Cohen, P. A. Newhouse… in Psychopharmacology (1987)

  8. No Access

    Article

    Cognitive effects of l-deprenyl in Alzheimer's disease

    Monoamine neurotransmitter systems, along with cholinergic systems, are known to play important roles in cognition, and are disrupted in at least some patients with dementia of the Alzheimer type (DAT). This s...

    P. N. Tariot, T. Sunderland, H. Weingartner, D. L. Murphy… in Psychopharmacology (1987)

  9. No Access

    Chapter and Conference Paper

    Selective Amine Oxidase Inhibitors: Basic to Clinical Studies and Back

    The monoamine oxidase (MAO)-inhibiting antidepressants, which have been in general clinical use in various parts of the world for the past 25 years, are all nonselective agents. They have marked effects on the...

    D. L. Murphy, T. Sunderland, N. A. Garrick… in Clinical Pharmacology in Psychiatry (1987)